PRESS RELEASE

Cellectis Announces RetroNectin® Supply and License Agreement with Takara Bio Inc.

New York, March 21, 2016 – Cellectis (Alternext: ALCLS – Nasdaq Global Market: CLLS), a biopharmaceutical company focused on developing immunotherapies based on gene edited CAR-T cells (UCART), has entered into a supply and license agreement with Takara Bio Inc. for recombinant human fibronectin fragment RetroNectin®.

Access to Takara Bio Inc.'s RetroNectin will secure Cellectis' manufacturing processes and expand the Company's UCART production capabilities. Under the terms of the agreement, RetroNectin, which is used for cell engineering, may be applied in the production of both R&D- and GMP-grade Cellectis' UCART product candidates.

Financial terms of the agreement are not disclosed.

"This agreement with Takara Bio will not only secure the manufacturing of Cellectis' robust product pipeline but also strengthen our key assets and capabilities in the cell engineering space" said Dr David Sourdive, EVP Corporate Development at Cellectis. "The partnership ultimately furthers our effort to provide universal CAR-Ts for immunotherapy patients all over the world."

"We are very grateful to provide RetroNectin for Cellectis' UCAR T-cell manufacturing process, which is one of the world's most advanced program in immunotherapy" added Dr. Yoh Hamaoka, Senior Executive Officer of Business Development at Takara Bio Inc. "We are pleased that RetroNectin contributes to the development of the emerging gene and cell therapy."

About Cellectis
Cellectis is a biopharmaceutical company focused on developing immunotherapies based on gene edited CAR T-cells (UCART). The company's mission is to develop a new generation of cancer therapies based on engineered T-cells. Cellectis capitalizes on its 16 years of expertise in genome engineering - based on its flagship TALEN® products and meganucleases and pioneering electroporation PulseAgile technology - to create a new generation of immunotherapies. CAR technologies are designed to target surface antigens expressed on cells. Using its life-science-focused, pioneering genome-engineering technologies, Cellectis' goal is to create innovative products in multiple fields and with various target markets. Cellectis is listed on the Nasdaq market (ticker: CLLS) and on the NYSE Alternext market (ticker: ALCLS). To find out more about us, visit our website: www.cellectis.com

Talking about gene editing? We do it.
TALEN® is a registered trademark owned by the Cellectis Group.

Restronectin® is a registered trademark owned by Takara Bio Inc.

For further information, please contact:

Media contacts
Jennifer Moore, VP Communications
Phone: +1 917-580-1088
email: media@cellectis.com

Caitlin Kasunich
KCSA Strategic Communications
Phone: +1 212.896.1241
email: ckasunich@kcsa.com

Investor relations contact
Simon Harnest, VP Finance and Investor Relations
Phone: +1 646-385-9008
email: simon.harnest@cellectis.com

Disclaimer

This press release and the information contained herein do not constitute an offer to sell or subscribe, or a solicitation of an offer to buy or subscribe, for shares in Cellectis in any country. This press release contains forward-looking statements that relate to the Company's objectives based on the current expectations and assumptions of the Company's management only and involve risk and uncertainties that could cause the Company to fail to achieve the objectives expressed by the forward-looking statements above.